Structure, functions of p-glycoprotein and its role in rational pharmacotherapy



Cite item

Full Text

Abstract

In the review of literature, the structure and functions of P-glycoprotein are characterized, features of its substrates, inductors and inhibitors and possibility of forecasting of belonging to them new medicinal substances are described, molecular mechanisms of activity changes of the transporter under the influence of various factors are presented.

About the authors

Elena Nikolaevna Yakusheva

Ryazan State Medical University

Email: e.yakusheva@rzgmu.ru
M. D., associate professor, head of the chair of pharmacology with a course of pharmacy and pharmacotherapy of faculty of additional professional education

Aleksey Vladimirovich Shulkin

Ryazan State Medical University

Email: alekseyshulkin@rambler.ru
Ph. D., assistant of the chair of pharmacology with a course of pharmacy and pharmacotherapy of faculty of additional professional education

Natal’ya Mikhaylovna Popova

Ryazan State Medical University

Email: p34-66@yandex.ru
Ph. D., assistant of the chair of pharmacology with a course of pharmacy and pharmacotherapy of faculty of additional professional education

Ivan Vladimirovich Chernyh

Ryazan State Medical University

Email: ivchernykh88@mail.ru
assistant of the chair of the general chemistry with a course of bioorganic and organic chemistry

Dmitriy Sergeevich Titov

Ryazan State Medical University

Email: i3762@yandex.ru
graduate student of the chair of pharmacology with a course of pharmacy and pharmacotherapy of faculty of additional professional education

References

  1. Бирюкова А. С., Якушева Е. Н., Щулькин А. В., Никифорова Л. В. Влияние тироксина на функциональную активность гликопротеина-Р в эксперименте // Российский медико-биологический вестник имени академика И. П. Павлова. - 2011. - № 4. - P. 49-53.
  2. Кукес В. Г., Грачев С. В., Сычев Д. А., Раменская Г. В. Метаболизм лекарственных средств. Научные основы персонализованной медицины: руководство для врачей. - М.: ГЭОТАР-Медиа, 2008.
  3. Середенин С. Б. Лекции по фармакогенетике. - М.: МИА, 2004.
  4. Штиль А. А. Развитие множественно лекарственной устойчивости как срочный ответ клетки на экзогенные воздействия // Биологические мембраны. - 2003. - Т. 20, № 3. - С. 236-243.
  5. Якушева Е. Н., Черных И. В., Бирюкова А. С. Характеристика гликопротеина-P как белка-транспортера лекарственных веществ // Российский медико-биологический вестник имени академика И. П. Павлова. - 2011. - № 3. - P. 142-148.
  6. Якушева Е. Н., Черных И. В. Влияние финастерида на функциональную активность гликопротеина-P в эксперименте // Российский медико-биологический вестник имени академика И. П. Павлова. - 2012. - № 4. - P. 46-50.
  7. Aller S. G., Yu J., Ward A. et al. Structure of P-glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding // Science. - 2009. - Vol. 323, № 5922. - P. 1718-1722.
  8. Al-Shawi M. K., Polar M. K., Omote N. et al. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein // Biol. Chem. - 2003. - Vol. 278. - P. 52629-52640.
  9. Ambudkar S. V., Kim I. V., Sauna Z. E. The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1) // Eur. J. Farm. Sci. - 2006. - Vol. 27, № 5. - P. 392-400.
  10. Ambudkar S. V., Dey S., Hrycyna C. et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter // Annu. Rev. Pharmacol. Toxicol. - 1999. - Vol. 39. - P. 361-398.
  11. Balram C., Huihua Li, Machin D. et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression // Br. J. Clin. Pharm. - 2005. - Vol. 60, № 2. - P. 159-171.
  12. Callaghan R., Berridge G., Ferry D. R., Higgins C. F. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface // Biochim. Biophys. Acta. - 1997. - Vol. 1328. - P. 109.
  13. Callen D. F., Baker E., Simmers R. N. et al. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1 // Hum. Genet. - 1987. - Vol. 77. - P. 142-144.
  14. Carrigos M., Mir L. M., Orlowski S. Competitive and Non-Competitive Inhibition of the Multidrug-Resistance-Associated P-glycoprotein ATPase // Eur. J. Biochem. - 1997. - Vol. 244, № 2. - P. 664-673.
  15. Chin L. W., Kroetz D. L. P-gp pharmacogenetics: progress, pitfalls and promise // Clin. Pharmacol. Ther. - 2007. - Vol. 81, № 2. - P. 265-269.
  16. Choi Y. H., Yu A. M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development // Curr. Pharm. Des. - 2013 May 13. URL: http://www.ncbi.nlm.nih.gov/pubmed/23688078 (дата обращения 22.12.2013).
  17. Chung J. W., Yang S. H., Choi J. S. Effects of lovastatin on the pharmacokinetics of nicardipine in rat // Biopharm. Drug Dispos. - 2010. - Vol. 31, № 7. - P. 436-341.
  18. Comerford K. M., Wallace T. J., Karhausen J. et al. Hypoxia-inducible Factor-1-dependent Regulation of the Multidrug Resistance (MDR1) Gene // Cancer Res. - 2002. - Vol. 62. - P. 3387.
  19. Ecker G. F., Stockner T., Chiba P. Computational models for prediction of interactions with ABC-transporters // Drug Discov Today - 2008. - Vol. 13, № 7-8. - P. 311-317.
  20. Ekins S., Kim R. B., Leake B. F. et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates // Mol Pharmacol. - 2002. - Vol. 61, № 5. - P. 974-981.
  21. Frankfurt O. S., Seckinger D., Sugarbaker E. V. Intercellular transfer of drug resistance // Cancer Res. - 1991. - Vol. 51, № 4. - P. 1190-1195.
  22. Geick A., Eichelbaum M., Burk O. Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin // J. Biol. Chem. - 2001. - Vol. 276. - P. 14581-14587.
  23. Germann U. A., Chambers T. C., Ambudcar S. V. et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells // Biol. Chem. - 1996. - Vol. 271. - P. 1708-1716.
  24. Glavy J. S., Horwitz S. B., Orr G. A. Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein // Biol. Chem. - 1997. - Vol. 272. - P. 5909-5914.
  25. Hamilton K. O., Yazdanian M. A., Audus K. L. Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands // Int. J. Pharm. - 2001. - Vol. 228, № 1-2. - P. 171-179.
  26. Hoffmeyer S., Burk O., von Richter O. et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo // Proc. Nat. Acad. Sci. - 2000. - Vol. 97, № 7. - P. 3473-3478.
  27. Hrycyna C. A., Ramachandra M., Ambudkar S. V. et al. Mechanism of action of human P-glycoprotein ATPase activity photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites // J. Biol. Chem. - 1998. - Vol. 273. - P. 16631-16634.
  28. Hudachek S. F., Gustafson D. L. Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice // J. Pharmacokinet. Pharmacodyn. - 2013. - Vol. 40, № 4. - P. 437-449.
  29. Jaganathan S. K. Can flavonoids from honey alter multidrug resistance? // Med. Hypotheses. - 2011. - Vol. 76, № 4. - P. 535-537.
  30. Jin S. Transcriptional Regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y // Mol. Cell. Biol. - 1998. - Vol. 18. - P. 4377-4384.
  31. Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell nutans // Biochem. Biophis. Acta - 1976. - Vol. 455, № 1. - P. 155-162.
  32. Kitada K., Yamasaki T. The MDR1/ABCB1 regional amplification in large inverted repeats with asymmetric sequences and microhomologies at the junction sites // Cancer Genet. Cytogenet. – 2007. - Vol. 178, № 2. - P. 120-127.
  33. Kitada K., Yamasaki T., Aikawa S. Amplification of the ABCB1 region accompanied by a short sequence of 200bp from chromosome 2 in lung cancer cells // Cancer Genet. Cytogenet. - 2009. - Vol. 194, № 1. - P. 4-11.
  34. Klepsch F., Chiba P., Ecker G. F. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein // PLoS Comput. Biol. - 2011. - Vol. 7, № 5. - e1002036.
  35. Klopman G., Shi L. M., Ramu A. Quantitative structure-activity relationship of multidrug resistance reversal agents // Mol. Pharmacol. - 1997. - Vol. 52. - P. 323.
  36. Kramer R., Weber T. K., Arceci R. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype // Br. J. Cancer. - 1993. - Vol. 71. - P. 670-676.
  37. Lee C. Y., Lai T. Y., Wu Y. M. et al. Gene expression of P-glycoprotein and cytochrome P450 3a4 in peripheral blood mononuclear cells and correlation with expression in liver // Transplant. Proc. - 2010. - Vol. 42, № 3. - P. 834-836.
  38. Lerner-Marmarosh N., Gimi K., Urbatsch I. L. et al. Large scale purification of detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of nucleotide binding properties of wild-type, Walker A, and Walker B mutant proteins // Biol. Chem. - 1999. - Vol. 274. - P. 34711-34718.
  39. Levchenko A., Mehta B. M., Niu X. et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells // Proc. Natl. Acad. Sci. USA. - 2005. - Vol. 102, № 6. - P. 1933-1938.
  40. Loo T. W., Bartlett M. C., Clark D. M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding // Biol. Chem. - 2003. - Vol. 278, № 16. - P. 13603-13606.
  41. Loo T. W., Clarke D. M. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein // J. Biol. Chem. -1994. - Vol. 269. - P. 7243-7248.
  42. Miller B. E., Machemer T., Lehotan M. et al. Tumor subpopulation interactions affecting melphalan sensitivity in palpable mouse mammary tumors // Cancer Res. - 1991. - Vol. 51, № 16. - P. 4378-4387.
  43. Miyazaki M., Kohno K., Uchiumi T. et al. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress // Biochem. Biophys. Res. Commun. - 1992. - Vol. 187. - P. 677-684.
  44. Pajeva I. K., Globisch C., Wiese M. Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors // Chem. Med. Chem. - 2009. - Vol. 4, № 11. - P. 1883-1896.
  45. Poongavanam V., Haider N., Ecker G. F. Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors // Bioorg. Med. Chem. - 2012. - Vol. 20, № 18. - P. 5388-5395.
  46. Robinson L. J., Roberts W. K., Ling T. T. et al. Human MDR1 protein over expression delays the apoptotic cascade in Chinese hamster ovary fibroblasts // Biochem. - 1997. - Vol. 36. - P. 11169-11178.
  47. Safa A. R., Stern R. K., Choy K. et al. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185-- Val-185 substitution in P-glycoprotein // Proc. Natl. Acad. Sci USA. - 1990. - Vol.87, № 18. - P.7225-7229.
  48. Schinkel A. H. et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug, transporting) P-glycoproteins // Proc. natl. acad. sci. - 1997. - Vol. 94. - P. 4028-4033.
  49. Schinkel A. H., Kemp S., Dolle M. et al. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein // Biol. Chem. - 1993. - Vol. 268, № 10. - Р. 7474-7481.
  50. Schwab M., Eichelbaum M., Fromm M. F. Genetic polymorphisms of the humanmdr1 drug transporter // Annu. Rev. Pharmacol. Toxicol. - 2003. - Vol. 43. - P. 285-307.
  51. Scotto K. W., Egan D. Transcriptional regulation of MDR genes // Cytotechnology. - 1998. - Vol. 27. - P. 257-269.
  52. Shapiro A. B., Ling V. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein // Eur. J. Biochem. - 1998. - Vol. 254. - P. 189-193.
  53. Sharom F. J. The P-glycoprotein multidrug transporter // Essays. Biochem. - 2011. - Vol. 50. - P. 161-178.
  54. Stein U., Walther W., Shoemaker R. N. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance // Br. J. Cancer. - 1996. - Vol.74, № 9. - P. 1384-1391.
  55. Tofilon P. J., Buckley N., Deen D. F. Effect of cell-cell interactions on drug sensitivity and growth of drug-sensitive and -resistant tumor cells in spheroids // Science. - 1984. - Vol. 226, № 4676. - P. 862-864.
  56. U. S. Food and Drug Administration, Center for Drug Evaluationand Research. Guidance for industry: drug interaction studiesdstudy design, data analysis, implications for dosing, and labeling recommendations. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362. Pdf (дата обращения 22.12.2013)
  57. Ueda K., Okamura N., Hirai M. et al. Human P-glycoprotein transports cortisol, aldosterone, anddexamethasone, but not progesterone // J. Biochem. - 1992. - Vol. 267, № 34. - P. 24248-24252.
  58. Ueda K., Taguchi Y., Morishima M. How does P-glycoprotein recognize its substrates // Semin. Cancer. Biol. - 1997. - Vol. 8. - P. 151-159.
  59. Ushigome F., Takanaga H., Matsuo H. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein // Eur. J. Pharmacol. - 2000. - Vol. 408, № 1. - P. 1-10.
  60. Van der Kolk D. M., de Vries E. G. E., van Putten W. L. J. et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia // Clin. Cancer Res. - 2000. - Vol. 6. - P. 3205-3214.
  61. Vilaboa N. E., Galan A., Troyano A. et al. Regulation ofmultidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). // J. Biol. Chem. - 2000. - Vol. 275. - P. 24970-24976.
  62. Wang Z., Chen Y., Liang H. et al. P-glycoprotein substrate models using support vector machines based on a comprehensive data set // J. Chem. Inf. Model. - 2011. - Vol. 51, № 6. - P. 1447-1456.
  63. Wartenberg M., Gronczynska S., Bekhite M. M. et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species // FASEB J. - 2003. - Vol. 17, № 3. - P. 503-505.
  64. Wessler D. J., Grip L. T., Mendell J., Giugliano R. P. The P-Glycoprotein Transport System and Cardiovascular Drugs // JACC. - 2013. - Vol. 61, № 25. - P. 2495-502.
  65. Yague E., Armesilla A. L. Harrison J. et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation // Biol. Chem. - 2003. - Vol. 278. - P. 10344-10352.
  66. Yang C. P., Cohen D., Greenberger L. M. et al. Differential transport properties of two mdr gene products are distinguished by progesterone // J. Biol. Chem. - 1990. - Vol.265, № 18. - P. 10282-10288.
  67. Yang C. P., DePinho S. G., Greenberger L. M. et al. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus // J. Biol. Chem. - 1989. - Vol. 264, № 2. - P. 782-728.
  68. Yuan H., Yang K., Li Y. et al. The structure and function of P-glycoprotein // Curr. Med. Chem. - 2010. - Vol. 17, № 8. - Р. 786-800.
  69. Z. Zhang, Wu J. Y., Hait W. N. et al. Regulation of the stability of P-glycoprotein by ubiquitination // Mol. Pharmacol. - 2004. - Vol. 66. - P. 395-403.
  70. Zhou S. F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition // Xenobiot. - 2008. - Vol. 8, № 7-8. - P. 802-832.

Copyright (c) 2014 Yakusheva E.N., Shulkin A.V., Popova N.M., Chernyh I.V., Titov D.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies